Sientra to Report First Quarter 2022 Financial Results on May 12, 2022
Sientra, Inc. (NASDAQ: SIEN) has announced its financial results for Q1 2022 will be released on May 12, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Sientra, Inc. (NASDAQ: SIEN) has announced its financial results for Q1 2022 will be released on May 12, 2022, after market close. A conference call to discuss these results is scheduled for 4:30 p.m. Eastern Time on the same day. Investors can access the call by dialing +1 (877) 270-2148 for domestic calls or +1 (412) 902-6510 for international calls, using conference ID 10166923. A live webcast will be available on their Investor Relations website and will be archived afterward.
Positive
- Scheduled conference call for Q1 2022 financial results indicates transparency and communication with investors.
Negative
- None.
Details
News Market Reaction – SIEN
The recorded move for SIEN in the trading session of this news was -0.69%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SANTA BARBARA, Calif., May 03, 2022 (GLOBE NEWSWIRE) -- Sientra, Inc. (NASDAQ: SIEN) (“Sientra” or the “Company”), a medical aesthetics company focused on enhancing lives by advancing the art of plastic surgery, today announced that it will release financial results for the first quarter of 2022 after the close of trading on Thursday, May 12, 2022. Sientra will host a conference call to discuss financial results the same day at 4:30 p.m. Eastern Time.
The dial-in numbers are +1 (877) 270-2148 for domestic callers and +1 (412) 902-6510 for international callers. The conference ID is 10166923.
A live webcast of the conference call will be available on the Investor Relations section of the Company's website at www.sientra.com. The webcast will be archived on the website following the completion of the call.
About Sientra
Headquartered in Santa Barbara, California, Sientra is a medical aesthetics company exclusively focused on plastic surgery. The Company mission is to offer proprietary innovations and unparalleled partnerships that radically advance how plastic surgeons think, work and care for their patients. Sientra has developed a broad portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company’s product portfolio includes its Sientra round and shaped breast implants, the first fifth generation breast implants approved by the FDA for sale in the United States, its ground-breaking Allox2® breast tissue expander with patented dual-port and integral drain technology, the AuraGen fat grafting system, and BIOCORNEUM®, the #1 performing, preferred and recommended scar gel of plastic surgeons(*).
Sientra uses its investor relations website to publish important information about the Company, including information that may be deemed material to investors. Financial and other information about Sientra is routinely posted and is accessible on the Company’s investor relations website at www.sientra.com.
(*) Data on file
Investor Relations Contact
Aman R. Patel, CFA
aman.patel@westwicke.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.